Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc.（DYN）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · DYN · 截至 2026年6月8日
活动摘要
买入笔数
7
P-Purchase only
卖出笔数
76
近12个月
买卖比
0.09
Buy/Sell (by trades)
整体情绪
Dyne Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
DYN 季度内部人买卖趋势
DYN 内幕交易卖出 · DYN 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · DYN CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
DYN 高管卖出股份 · DYN 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 3, 2026 | Posner Brian S Director | Purchase | 2,500 | $44K | Form 4 |
| May 26, 2026 | Posner Brian S Director | Purchase | 2,000 | $36K | Form 4 |
| May 20, 2026 | Posner Brian S Director | Purchase | 2,500 | $43K | Form 4 |
| May 13, 2026 | Friedl-Naderer Johanna Chief Commercial Officer | Sale | 228 | $4K | Form 4 |
| May 13, 2026 | Kerr Douglas Chief Medical Officer | Sale | 1,564 | $29K | Form 4 |
| May 13, 2026 | Lucera Erick CFO | Sale | 1,448 | $27K | Form 4 |
| May 13, 2026 | Cox John CEO & President · Director | Sale | 3,311 | $61K | Form 4 |
| May 4, 2026 | Rhodes Jason P Director | Sale | 6,241 | $112K | Form 4 |
| May 5, 2026 | Rhodes Jason P Director | Sale | 6,081 | $110K | Form 4 |
| May 6, 2026 | Rhodes Jason P Director | Sale | 43,621 | $793K | Form 4 |
| May 4, 2026 | Rhodes Jason P Director | Sale | 3,136 | $56K | Form 4 |
| May 5, 2026 | Rhodes Jason P Director | Sale | 3,056 | $55K | Form 4 |
| May 6, 2026 | Rhodes Jason P Director | Sale | 21,926 | $399K | Form 4 |
| May 4, 2026 | Rhodes Jason P Director | Sale | 2,466 | $44K | Form 4 |
| May 5, 2026 | Rhodes Jason P Director | Sale | 2,403 | $43K | Form 4 |
| May 6, 2026 | Rhodes Jason P Director | Sale | 17,244 | $313K | Form 4 |
| May 4, 2026 | Rhodes Jason P Director | Sale | 61 | $1K | Form 4 |
| May 5, 2026 | Rhodes Jason P Director | Sale | 60 | $1K | Form 4 |
| May 6, 2026 | Rhodes Jason P Director | Sale | 428 | $8K | Form 4 |
| Apr 28, 2026 | Rhodes Jason P Director | Sale | 119,115 | $2.19M⚡ | Form 4 |
| Apr 28, 2026 | Rhodes Jason P Director | Sale | 52 | $988 | Form 4 |
| Apr 28, 2026 | Rhodes Jason P Director | Sale | 59,870 | $1.10M⚡ | Form 4 |
| Apr 28, 2026 | Rhodes Jason P Director | Sale | 26 | $494 | Form 4 |
| Apr 28, 2026 | Rhodes Jason P Director | Sale | 47,082 | $865K | Form 4 |
| Apr 28, 2026 | Rhodes Jason P Director | Sale | 21 | $399 | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 DYN 内幕交易
DYN 内幕交易
Dyne Therapeutics, Inc.（DYN）内幕交易数据来源于公司内部人（包括Rhodes Jason P (Director), Kersten Dirk (Director), Cox John (CEO & President · Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。DYN内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Dyne Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
DYN 内幕交易 · 5个问题Dyne Therapeutics, Inc.（DYN）的内部人包括高管和董事，如Rhodes Jason P (Director), Kersten Dirk (Director), Cox John (CEO & President · Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026